William Blair & Company
ELDN icon

William Blair & Company’s Eledon Pharmaceuticals ELDN Stock Holding History

William Blair & Company’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Buy
14,943
+427
+3% +$1.55K ﹤0.01% 1754
2026
Q1 		$44.7K Buy
+14,516
New +$34.2K ﹤0.01% 1708
2015
Q2 		– Sell
-113
Closed -$206K – 2208
2015
Q1 		$206K Sell
113
-122
-52% -$269K ﹤0.01% 2013
2014
Q4 		$560K Buy
+235
New +$558K ﹤0.01% 1660

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

William Blair & Company's ELDN Position: Q2 2026 in Review

William Blair & Company increased its Eledon Pharmaceuticals (ELDN) stake by 2.9% in Q2 2026, buying an estimated $1.55K and bringing the position to 14,943 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1754.

William Blair & Company first reported a position in ELDN in Q4 2014 and has held it in 4 quarters since. The position peaked at $560K in Q4 2014. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • William Blair & Company held 14,943 shares of Eledon Pharmaceuticals worth $58.9K as of Q2 2026.
  • William Blair & Company bought 427 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.55K.
  • Eledon Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1754 holding.
  • William Blair & Company first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • William Blair & Company's Eledon Pharmaceuticals position peaked at $560K in Q4 2014.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.